Drug blueprints to treat and cure all diseases for all people

Scroll Down

Our Mission

POLARISqb will revolutionize drug design by joining Quantum Computing with AI and Precision Medicine. Our platform will produce up to 100 drug blueprints per year. We will compress the lead time for preclinical drug candidates from 5 years to 4 months, enabling real time adaptability to the precision medicine market. POLARISqb will own an IP portfolio of drug assets to license, sell, or develop internally.

Quantum Computing + AI

POLARISqb will use Quantum Computing to search unstructured, exponentially large datasets to explore novel chemical space, and create new drugs. Artificial Intelligence tools, especially Machine Learning (AI/ML) algorithms utilizing Big Data, are used to remove drug toxicity effects. Platform automation and scale will bring the power of these tools to bear on our mission.

Precision Medicine

The cost of personal genome sequencing is decreasing and is projected to be less than $1,000 per person by 2020. This allows for a better understanding of disease biology, and discovery of more specific disease pathways leading to smaller and more precise patient groups. This Precision Medicine toolbox identifies the proteins that POLARISqb will use to create the drug blueprints in our portfolio.

Chemistry + Time

Most drugs are small molecules that have been optimized to manipulate the right biology (alter disease state) without harming the rest of the body. Developing drugs is currently a lengthy (10 years) and expensive (> $1B) process. At POLARISqb, automation and scale will significantly shorten and lower the cost of the process. Reducing cost and time to market of our drug candidates enhances the value of our IP portfolio.

Our Vision

We’re transforming health for people everywhere, by the fast creation of drug blueprints for all human proteins, disease pathways, genetic mutations and pathogens.

We unite the powers of Quantum Computing, AI and Precision Medicine to search chemical space and create novel molecular drugs for specific proteins and diseases.

Team

News

October 12, 2020

POLARISqb selected to participate in Founder Gym, prestigious global accelerator for underrepresented founders


Press Release

March 16, 2020

POLARISqb and Fujitsu announces pioneering drug discovery platform to speed up the process of bringing new drugs to market

Press Release

March 16, 2020

De Novo Digital Drug Design Platform



A new quantum-inspired platform that brings together pioneering technology from Fujitsu and POLARISqb to significantly improve the speed and chemical diversity of small molecule lead discovery, tested on the Dengue Fever polymerase


Case Study

March 16, 2020

Fujitsu’s Director of Innovation & Health, Patrick Stephenson, talks about Fujitsu’s partnership with POLARISqb and their motivations behind developing the platform

Blog

March 18, 2020

WRAL TechWire: Durham quantum-computing startup launches drug discovery platform it says is much faster

Media Coverage

Careers